Rabeprazole Sodium BP 20 mg
Business Unit: Human
Medicine Type: Tablet
Generic Name: Rabeprazole Sodium BP 20 mg
Therapeutic Class: Proton Pump Inhibitor (PPI)
Indication: The active ingredient in Robust is Rabeprazole sodium, a rapid acting proton pump inhibitor (PPI). Robust is indicated for- i) Duodenal ulcer ii) Benign gastric ulcer iii) Duodenal ulcer and benign gastric ulcer associated with H. pylori infection iv) Healing of erosive or ulcerative Gastroesophageal Reflux Disease (GERD v) Treatment of symptomatic GERD vi) Maintenance of healing of erosive or ulcerative GERD vii) Prevention or treatment of NSAID-induced ulcers viii) Zollinger-Ellison Syndrome.
Dosage & Administration: i) Duodenal ulcer: Robust 20 mg tablet in the morning is indicated for 4 weeks treatment in the healing and symptomatic relief of duodenal ulcer. Most patients heal within 4 weeks. ii) Benign gastric ulcer: 20 mg daily in the morning for 6 weeks, followed by a further 6 weeks if not fully cured. iii) Duodenal ulcer and benign gastric ulcer associated with H. pylori infection: Robust in combination with Amoxicillin and Clarithromycin as a three drug regimen is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease. Rabeprazole offers a faster therapy option than other PPIs, up to 10 to 14 days 20 mg once daily. iv) Healing of erosive or ulcerative Gastroesophageal Reflux Disease (GERD): 20 mg daily in the morning 4 to 8 weeks. Those patients who have not healed after 8 weeks of treatment, an additional 8-week course of Robust may be considered. v) Treatment of symptomatic GERD: The recommended adult oral dose of Robust is 20 mg once daily for 4 weeks. If symptoms do not resolve completely after 4 weeks, an additional course of treatment may be considered. vi) Maintenance of healing of erosive or ulcerative GERD: Robust is indicated for maintaining healing and reduction in relapse rates of heartburn symptoms in patients with erosive or ulcerative GERD maintenance. Controlled studies do not extend beyond 12 months. vii) Prevention or treatment of NSAID-induced ulcers: Robust 20 mg tablet once daily, in patients receiving treatment with NSAIDs. viii) Zollinger-Ellison Syndrome: The recommended adult oral starting dose is 60 mg once a day. Doses should be adjusted to individual patient needs and should continue for as long as clinically indicated. Some patients may require divided doses. Doses up to 100 mg once daily and 60 mg twice daily have been administered.
Preparation: Robust 20 tablet: Each box contains 6 Alu-Alu blister strips of 15 tablets.